ISSN 2407-2230 | E-ISSN 1907-3062 | Universa Medicina content is searchable on DOAJ, Google Scholar, and OAI

Aspirin for primary prevention of cardiovaascular events: what are the evidances?

Yenny Yenny
Submission date: Wednesday, 29 May 2019
Published date: Thursday, 29 August 2019
DOI: http://dx.doi.org/10.18051/UnivMed.2019.v38.145-146

Abstract


Cardiovascular disease (CVD) is the leading cause of mortality in the United States, accounting for about 1 in 3 deaths.(1) In view of the healthcare and economic burdens of cardiovascular disease, the public health aim should be the prevention of cardiovascular events through risk factor optimization.

Full Text:

PDF

References


Mozaffarian D, Benjamin EJ, Go AS, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee Heart disease and stroke statistics—2015 update: a report from the American Heart Association. Circulation 2015; 131:e29-322. doi: 10.1161/CIR.0000000000000 152.

Gargiulo G, Windecker S, Vranckx P, Gibson CM, Mehran R, Valgimigli M. A critical appraisal of aspirin in secondary prevention: is less more? Circulation 2016;134:1881–1906. doi: 10.1161/CIRCULATIONAHA.116.023952.

Gaziano JM, Brotons C, Coppolecchia R, et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet 2018;392:1036-46. doi: 10.1016/S0140-6736(18) 31924-X.

Bowman L, Mafham M, Wallendszus K, et al. Effects of aspirin for primary prevention in persons with diabetes mellitus. New Engl J Med 2018;379:1529-39. doi: 10.1016/j.jvs.2018.10.072.

McNeil JJ, Wolfe R, Woods RL, et al. Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. New Engl J Med 2018;379:1509-18. doi: 10.1056/NEJMoa1805819.

Lin MH, Lee CH, Lin C, et al. Low-dose aspirin for the primary prevention of cardiovascular disease in diabetic individuals: a meta-analysis of randomized control trials and trial sequential analysis. J Clin Med 2019;8:pii.E609. doi: 10.3390/jcm8050609.

Rothwell PM, Cook NR, Gaziano JM, et al. Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials. Lancet 2018;392:387-99. DOI: https://doi.org/10.1016/S0140-6736(18)31133-4.

Piepoli MF, Hoes AW, Agewall S, et al. European guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016;37:2315-81. doi: 10.1093/eurheartj/ehw106.

Bibbins-Domingo K. US Preventive Services Task Force. Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: US Preventive Services Task Force Recommendation Statement. Ann Inter Med 2016;164:836-45. doi: 10.7326/M16-0577.

Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the primary prevention of cardiovascular disease. Circulation 2019: CIR0000000000000677. doi: 10.1161/CIR. 0000000000000677.

Zheng SL, Alistair J. Roddick AJ. Association of aspirin use for primary prevention with cardiovascular events and bleeding events: a systematic review and meta-analysis. JAMA 2019; 321:277-87. doi: 10.1001/jama.2018.20578.


Refbacks

  • There are currently no refbacks.


Copyright (c) 2019 Universa Medicina

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Creative Commons License
Universa Medicina by Faculty of Medicine, Trisakti University is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Based on a work at https://univmed.org/ejurnal/index.php/medicina/